Fibrosis Pathogenesis and Resolution: From Mechanisms to Therapies

摘要 请求支持Keystone研讨会，题为纤维化的发病机制和解决方案： 从机制到疗法，由David Lagares博士、Boris Hinz博士和Carine Boustany博士组织。这个 会议将于2023年3月19日至23日在加拿大艾伯塔省班夫举行。 人类纤维性疾病的特征是进行性组织疤痕形成，以应对不堪重负的或 慢性损伤，最终导致器官衰竭和死亡。纤维化疾病导致医疗费用高达 每年100亿美元。这些成本预计将随着我们的人口老龄化而进一步增加，我们的 诊断纤维化疾病的能力和出现新的传染性病原体，如SARS-CoV-2， 可促进肝纤维化的发展。因此，这次会议旨在确定共同的 以及不同侮辱(例如，病毒感染、创伤、致癌)时导致纤维化的不同机制 受伤)。本次会议还将讨论外地新出现的下列主题：1) 放大和维持组织纤维化，如衰老、表观遗传学和机械生物学，2)与 成纤维细胞在组织修复和纤维化中的异质性，以及3)理解促进纤维化的机制 解决和再生，以设计新的战略，真正再生纤维化的器官。本次论坛还将 关注主要的临床挑战，包括缺乏可靠的纤维化生物标记物、安全终点和临床 试验终点。这些领域的进展将打破将抗纤维化疗法从 从长椅到床边。本次Keystone研讨会将加速纤维化研究和抗纤维化药物 通过促进来自不同领域的医生和科学家之间的跨学科互动来发现 无论是学术机构还是制药和生物技术行业。最后，这次会议将举行 NAFLD/NASH的代谢和分子机制。联席会议将突出当前 与NASH和肝纤维化相关的关键生物学过程相关的证据。来自两个国家的参与者 会议将有机会通过共享会议、用餐时间和晚间海报进行网络交流 会话。

ABSTRACT Support is requested for a Keystone Symposia conference entitled Fibrosis Pathogenesis and Resolution: From Mechanisms to Therapies, organized by Drs. David Lagares, Boris Hinz and Carine Boustany. The conference will be held in Banff, Alberta, Canada from March 19 - 23, 2023. Human fibrotic diseases are characterized by progressive tissue scarring in response to overwhelming or chronic injury, ultimately leading to organ failure and death. Fibrotic diseases cause healthcare costs reaching $10 billion per year. These costs are expected to further increase with our aging populations, our increasing capacity to diagnose fibrotic disorders and the emergence of novel infectious agents such as SARS-CoV-2, which can promote the development of fibrosis. Therefore, this conference was designed to identify common and distinct mechanisms driving fibrosis in response to different insults (e.g., viral infection, trauma, oncogenic injury). This conference will also address the following emerging themes in the field: 1) the mechanisms which amplify and perpetuate tissue fibrosis, such as aging, epigenetics, and mechanobiology, 2) the relevance of fibroblast heterogeneity in tissue repair and fibrosis, and 3) understanding the mechanisms promoting fibrosis resolution and regeneration to devise novel strategies to truly regenerate fibrotic organs. This forum will also focus on major clinical challenges including the lack of robust fibrosis biomarkers, safety endpoints, and clinical trial endpoints. Advances in these areas will break down barriers in translating anti-fibrotic therapies from bench to bedside. This Keystone Symposia conference will accelerate fibrosis research and anti-fibrotic drug discovery by fostering interdisciplinary interactions among a diverse group of physicians and scientists from both academic institutions and the pharmaceutical and biotech industry. Finally, this conference will be held jointly with Metabolic and Molecular Mechanisms of NAFLD/NASH. The joint conference will highlight current evidence linking key biological processes involved in NASH and liver fibrosis. Participants from both conferences will have the opportunity to network through shared sessions, mealtimes, and evening poster sessions.